Professional
Added to YB: 2025-10-13
Pitch date: 2025-09-30
ALNY [neutral]
Alnylam Pharmaceuticals, Inc.
-25.58%
current return
Author Info
No bio for this author
Company Info
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
Market Cap
$41.7B
Pitch Price
$456.00
Price Target
N/A
Dividend
N/A
EV/EBITDA
66.11
P/E
134.94
EV/Sales
11.24
Sector
Biotechnology
Category
growth
Orbis Global Equity Portfolio Holding: Alnylam Pharmaceuticals, Inc.
ALNY (holding update): RNAi therapeutics leader with 4 marketed + 2 partnered in-house medicines. New ATTR-CM drug Amvuttra exceeded Q1 commercial expectations by wide margin, validating best-in-class thesis. Strong sales ramp puts co on track for 2024 profitability, positioning among biotech giants like Vertex/Gilead.
Read full article (1 min)